Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.

Faculty in this hub lead the design, coordination, and analysis of clinical trials for cancer treatment, survivorship, vaccine efficacy, infectious disease prevention and treatment, and cancer ...

Dr. Adil Shamoo does an admirable job of debunking the legitimacy of using "equipoise" to justify the conduct of phase 1 clinical trials and, by extension, phase 2 and 3 clinical trials. [1] To the ...

Our country is seeing a growth in phase 1 clinical trials conducted by public hospitals to test new drugs and devices.

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...

Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, ...

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent ...